Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Clinics ; 64(12): 1187-1193, 2009. tab
Article Dans Anglais | LILACS | ID: lil-536221

Résumé

OBJECTIVES: The aim of the present study was to investigate the effectiveness of Samarium153-particulate hydroxyapatite radiation synovectomy in rheumatoid arthritis patients with chronic knee synovitis. METHODS: Fifty-eight rheumatoid arthritis patients (60 knees) with chronic knee synovitis participated in a controlled double-blinded trial. Patients were randomized to receive either an intra-articular injection with 40 mg triamcinolone hexacetonide alone (TH group) or 40 mg triamcinolone hexacetonide combined with 15 mCi Samarium153-particulate hydroxyapatite (Sm/TH group). Blinded examination at baseline (T0) and at 1 (T1), 4 (T4), 12 (T12), 32 (T32), and 48 (T48) weeks post-intervention were performed on all patients and included a visual analog scale for joint pain and swelling as well as data on morning stiffness, flexion, extension, knee circumference, Likert scale of improvement, percentage of improvement, SF-36 generic quality of life questionnaire, Stanford Health Assessment Questionnaire (HAQ), Lequesne index, use of non-steroidal anti-inflammatory drugs or oral corticosteroids, events and adverse effects, calls to the physician, and hospital visits. RESULTS: The sample was homogeneous at baseline, and there were no withdrawals. Improvement was observed in both groups in relation to T0, but no statistically significant differences between groups were observed regarding all variables at the time points studied. The Sm/TH group exhibited more adverse effects at T1 (p<0.05), but these were mild and transitory. No severe adverse effects were reported during follow-up. CONCLUSION: Intra-articular injection of Samarium153-particulate hydroxyapatite (15 mCi) with 40 mg of triamcinolone hexacetonide is not superior to triamcinolone hexacetonide alone for the treatment of knee synovitis in patients with rheumatoid arthritis at 1 y of follow-up.


Sujets)
Femelle , Humains , Mâle , Adulte d'âge moyen , Anti-inflammatoires/effets indésirables , Polyarthrite rhumatoïde/radiothérapie , Hydroxyapatites/effets indésirables , Articulation du genou , Radio-isotopes/effets indésirables , Samarium/effets indésirables , Synovite/radiothérapie , Anti-inflammatoires/administration et posologie , Polyarthrite rhumatoïde/traitement médicamenteux , Maladie chronique , Association médicamenteuse , Méthodes épidémiologiques , Hydroxyapatites/administration et posologie , Qualité de vie , Radio-isotopes/usage thérapeutique , Samarium/administration et posologie , Synovite/traitement médicamenteux , Triamcinolone acétonide/administration et posologie , Triamcinolone acétonide/effets indésirables , Triamcinolone acétonide/analogues et dérivés
SÉLECTION CITATIONS
Détails de la recherche